Evidence map›Paper›PMID 36649326›Full record

ReviewObstetrics and gynecology2023

Safety and Efficacy of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines During Lactation.

Lydia L Shook, Andrea G Edlow

Open access · greenAbstract readReview
In one paragraph

Review in Obstetrics and gynecology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Lydia L ShookDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, and the Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts.
Andrea G Edlow
Twitter (United States) · US

Funding

Research Project 2 The pregnancy AdaptOMEU19AI167899 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Andrea Goldberg Edlow · 2022 to 2026
$14.7M
Sex Differences in Fetal Brain-Placental Immune Programming in Maternal ObesityR01HD100022 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI EDLOW, ANDREA GOLDBERG · 2019 to 2021
$2.0M
Transdisciplinary Harvard WRHR Career Development for Gynecologists and ObstetriciansK12HD103096 · NICHD · BRIGHAM AND WOMEN'S HOSPITAL · PI NOUR, NAWAL M. · 2020 to 2024
$1.5M
NIAID NIH HHS U19 AI167899NICHD NIH HHS K12 HD103096NICHD NIH HHS R01 HD100022
6 · The paper itself

Abstract

In this review, we summarize the data on the safety and side-effect profile of coronavirus disease 2019 (COVID-19) vaccines during lactation to date, review what is known about mRNA vaccine components in breast milk, and discuss the efficacy of COVID-19 vaccines in providing immune protection for the breastfeeding infant. The Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists recommend that lactating individuals receive COVID-19 mRNA vaccines and stay up to date on booster doses, including the bivalent COVID-19 booster. The lack of serious side effects in mothers or infants across numerous large studies and registries of COVID-19 vaccination in pregnancy and lactation is reassuring. Although small quantities of mRNA may be transiently detectable in breast milk after maternal vaccination, there are no data demonstrating that vaccine mRNA can survive the infant gastrointestinal tract and no evidence that breast milk from lactating individuals who have received a COVID-19 mRNA vaccine can cause harm to breastfeeding infants. In contrast, numerous studies demonstrate that the breast milk of vaccinated individuals contains severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific functional antibodies and T cells, which benefit the breastfeeding infant's developing immune system. Transfer of SARS-CoV-2-specific antibodies from mother to infant is highest when vaccination occurs during pregnancy compared with lactation, because the breastfeeding infant receives both long-lasting antibodies through the placenta and breast-milk antibodies through breast milk. With clear data demonstrating efficacy and safety and no data demonstrating harm to mother or infant after COVID-19 vaccine administration during lactation, any recommendations to avoid vaccination while breastfeeding or to withhold breast milk from the infant for any period of time after vaccination are not supported by available evidence.

Indexed as

COVID-19COVID-19 VaccinesLactationAntibodies, ViralBreast FeedingFemaleHumansInfantMothersPregnancyRNA, MessengerSARS-CoV-2Antibodies, ViralCOVID-19 VaccinesRNA, Messenger

Identifiers

PMID36649326
PMCPMC9975040
OpenAlexW4316926702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.